Traditional Chinese medicine: one week of innovation, one week of value oriented development
On January 30, the Ministry of industry and information technology, the national development and Reform Commission, the Ministry of science and technology and other nine departments jointly issued the “14th five year plan” for the development of pharmaceutical industry, which is expected to benefit the traditional Chinese medicine sector for a long time. The plan brings traditional Chinese medicine into the key field of pharmaceutical industry development, which shows China’s determination to focus on the development of traditional Chinese medicine industry. The traditional Chinese medicine sector is expected to benefit from the policy for a long time and has long-term investment value; It is emphasized to promote the integrity and innovation of traditional Chinese medicine, increase investment, support the development of innovative products, support the inheritance, innovation and development of traditional Chinese medicine, and the approval of new traditional Chinese medicine is expected to be further accelerated; It is emphasized to focus on the development of traditional Chinese medicine compound preparations based on ancient classic prescriptions and the transformation of traditional Chinese medicine preparations in medical institutions into new traditional Chinese medicine, encourage the secondary development of listed traditional Chinese medicine and develop large varieties of traditional Chinese medicine; Encourage enterprises to “one go” and strengthen one’s cooperation with the one belt, one road, and develop new markets, and get out of the new growth curve.
One week’s view: the pharmaceutical upstream industry chain has high R & D investment + independent control, and domestic enterprises usher in a high light moment
The plan clearly states that “the R & D investment of the whole industry will increase by more than 10% annually; by 2025, the proportion of new sales of innovative products in the increment of operating revenue of the whole industry will further increase” and “The industrial chain and supply chain are stable and controllable. The advantages of large-scale and systematic pharmaceutical manufacturing have been further consolidated. Breakthroughs have been made in a number of key common technologies for industrialization, positive results have been achieved in making up for weaknesses in key areas, and a number of key enterprises with leading and driving ability of industrial ecology in subdivided areas have been cultivated”. Life science reagent is the basic material of life science research and development. As a consumable tool, it is widely used in life science research activities. We are optimistic that under the background of increasing investment in the biomedical industry, the reagent industry as a “water seller” of basic scientific research is expected to maintain rapid growth. At the same time, it is expected to fully benefit the upstream scientific instruments, pharmaceutical equipment and separation and purification fillers.
One week’s view: the pharmaceutical business should actively develop new business forms, explore the interconnection between prescriptions of medical institutions and drug retail information, and promote the outflow of prescriptions
The plan proposes to explore the interconnection of prescription and drug retail information of medical institutions, which is conducive to accelerating the development of out of hospital market. Under the general trend of prescription outflow, the head pharmacy has the advantage of undertaking prescription outflow, and seizes the market opportunity through the layout of hospital side stores, the construction of DTP pharmacy and the construction of stores with overall medical insurance qualification for chronic diseases. In addition, the plan proposes to promote the construction of a digital management system covering disease diagnosis and treatment, drug distribution, medical institution charges, medical insurance settlement and other links, so that the living space of small and medium-sized pharmacies with weak capital and technical strength will be further squeezed, Only the leading retail outlets and pharmaceutical distribution enterprises that are upgrading the digital system will be able to better adapt to the construction of unified digital management system and smoothly integrate into the new environment of “Internet plus medicine”.
Recommended and beneficial objects
Recommended targets: Henan Lingrui Pharmaceutical Co.Ltd(600285) , Tasly Pharmaceutical Group Co.Ltd(600535) , Xiangyumedicalco.Ltd(688626) , Pharmablock Sciences (Nanjing) Inc(300725) , Shanghai Haoyuan Chemexpress Co.Ltd(688131) , Apeloa Pharmaceutical Co.Ltd(000739) , Sino Biological Inc(301047) , Lbx Pharmacy Chain Joint Stock Company(603883) , Yifeng Pharmacy Chain Co.Ltd(603939) (the above ranking is not in order).
Beneficiaries: Youcare Pharmaceutical Group Co.Ltd(688658) , Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) , Jiangsu Kanion Pharmaceutical Co.Ltd(600557) , Guiyang Xintian Pharmaceutical Co.Ltd(002873) , Chinese traditional medicine, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) , gushengtang, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) , Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) , Yunnan Baiyao Group Co.Ltd(000538) , China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) , Tofflon Science And Technology Group Co.Ltd(300171) , Truking Technology Limited(300358) , Shinva Medical Instrument Co.Ltd(600587) , Suzhou Nanomicro Technology Co.Ltd(688690) , Yixintang Pharmaceutical Group Co.Ltd(002727) , Dashenlin Pharmaceutical Group Co.Ltd(603233) , Yunnan Jianzhijia Health-Chain Co.Ltd(605266) .
Risk tip: the black swan incident and the deterioration of the epidemic situation in the industry affect production and operation.
